Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Understanding the cost-effectiveness of bivalirudin.

Amin AP, Magnuson EA.

Heart. 2012 Jul;98(14):1037-9. doi: 10.1136/heartjnl-2012-301649. No abstract available.

PMID:
22739634
2.

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.

Schwenkglenks M, Toward TJ, Plent S, Szucs TD, Blackman DJ, Baumbach A.

Heart. 2012 Apr;98(7):544-51. doi: 10.1136/heartjnl-2011-301323. Epub 2012 Feb 7.

3.

Bivalirudin and DES: a PCI strategy that pays.

Applegate RJ.

J Invasive Cardiol. 2007 Feb;19(2):69-70. No abstract available.

PMID:
17268040
4.

Economic impact of new interventional therapies: are we asking the right questions?

Kong DF, Mark DB.

J Am Coll Cardiol. 2004 Nov 2;44(9):1809-11. No abstract available.

5.

Bivalirudin for patients with ST-elevation myocardial infarction.

Dwivedi G, Steed R, Chong AY.

Lancet. 2011 Dec 3;378(9807):1915; author reply 1915-6. doi: 10.1016/S0140-6736(11)61835-7. No abstract available.

PMID:
22137838

Supplemental Content

Support Center